Validation of the novel transdermal arterial gasotransmitter sensor (TAGS™) system in measuring transdermal hydrogen sulfide in human subjects.
Validation of the novel transdermal arterial gasotransmitter sensor (TAGS™) system in measuring transdermal hydrogen sulfide in human subjects.
复制标题
验证新型透皮动脉气体递质传感器 (TAGS™) 系统在人体中测量透皮硫化氢的效果。
DOI：
10.1016/j.sbsr.2022.100523
复制
发表时间：
2022
影响因子：
5.3
通讯作者：
Shekarriz,R
中科院分区：
文献类型：
--
作者：
Matheson,BT;Osofsky,RB;Friedrichsen,DM;Brooks,BJ;Clark,RM;Kanagy,NL;Shekarriz,R
一种新型的非侵入性系统已经被开发出来，用于测量人体上肢和下肢经皮释放的硫化氢（H2S）。经皮动脉气体传输传感器（TAGS™）先前已被证明可以检测到与生理测量相关的低水平H2S，范围在1至100 ppb之间（Shekarriz et al. 2020）。本研究旨在将其检测透皮H2S的测量精度与市售的化学发光装置Ecotech Serinus 55 TRS™进行比较。虽然TAGS™进行了现场和实时采样，但本文的比较研究收集了10名年龄在30至60岁之间的健康人类受试者的下臂排放的气体。每个个体的三个重复样本在一个密封的10 L Tedlar®袋中收集30分钟，以允许两个设备从相同的样本中读取。TAGS™系统的读数与Serinus™装置获得的值高度相关，均在0.31 ppb/min和2.21 ppb/min之间，相关系数R2= 0.8691,p< 0.0001。这些结果表明，TAGS™可以特异性和准确地测量透皮H2S。由于血管内皮细胞是已知的H2S来源，因此TAGS™测量可以提供一种非侵入性的方法来检测内皮功能障碍，即外周动脉疾病（PAD）和微血管疾病的潜在原因。TAGS™具有潜在的临床应用，如监测疑似血管疾病患者的皮肤血管灌注或监测治疗期间伤口愈合的进展，这对患有动脉钙化限制检测选择的糖尿病患者具有特别的价值。
A novel non-invasive system has been developed to measure transdermally emitted hydrogen sulfide (H2S) from the upper and lower limbs of human subjects. The transdermal arterial gasotransmitter sensor (TAGS™) has previously been shown to detect low levels of H2S ranging between 1 and 100 ppb considered relevant for physiological measurements (Shekarriz et al. 2020). This study was designed to compare its measurement precision in detecting transdermal H2S to a commercially available chemiluminescent device, the H2S-selective Ecotech Serinus 55 TRS™. Although TAGS™ does in-situ and real-time sampling, the comparative studies in this paper collected gases emitted from the lower arm of 10 heathy human subjects between the ages of 30 and 60. Three replicate samples of each individual were collected for 30 min in a sealed 10 L Tedlar® bag to allow readings from the same sample by both devices. Readings from the TAGS™ system correlated strongly with the values obtained from the Serinus™ device, both ranging between 0.31 ppb/min and 2.21 ppb/min, with a correlation coefficient of R2= 0.8691,p< 0.0001. These results indicate that TAGS™ measures transdermal H2S specifically and accurately. Because vascular endothelial cells are a known source of H2S, TAGS™ measurements may provide a non-invasive means of detecting endothelial dysfunction, the underlying cause of peripheral artery disease (PAD) and microvascular disease. TAGS™ has potential clinical applications such as monitoring skin vascular perfusion in individuals with suspected vascular disease or to monitor progression of wound healing during treatment, which is of particular value in diabetic patients with calcified arteries limiting detection options.